Although the loss of function of all these tumor suppressors is common in advanced prostate cancer [49], deletion or mutation of any two of the combination of PTEN, RB1, TP53 predicts poor response to AR-targeted therapy and decreased overall survival [50]. This evidence concerns the gene AR and prostate cancer.